gms | German Medical Science

69. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC)
Joint Meeting mit der Mexikanischen und Kolumbianischen Gesellschaft für Neurochirurgie

Deutsche Gesellschaft für Neurochirurgie (DGNC) e. V.

03.06. - 06.06.2018, Münster

Article

Send article

Impact of carmustine implantation in first recurrence of glioblastoma patients – a retrospective monocentric analysis

Meeting Abstract

Search Medline for

  • Sabrina Köber - Heinrich-Heine-Universität, Universitätsklinikum, Klinik für Neurochirurgie, Düsseldorf, Deutschland
  • Benedikt Kremer - Heinrich-Heine-Universität, Universitätsklinikum, Klinik für Neurochirurgie, Düsseldorf, Deutschland
  • Marcel Alexander Kamp - Heinrich-Heine-Universität, Universitätsklinikum, Klinik für Neurochirurgie, Düsseldorf, Deutschland
  • Hans-Jakob Steiger - Heinrich-Heine-Universität, Universitätsklinikum, Klinik für Neurochirurgie, Düsseldorf, Deutschland
  • Michael Sabel - Heinrich-Heine-Universität, Universitätsklinikum, Klinik für Neurochirurgie, Düsseldorf, Deutschland
  • Marion Rapp - Heinrich-Heine-Universität, Universitätsklinikum, Klinik für Neurochirurgie, Düsseldorf, Deutschland

Deutsche Gesellschaft für Neurochirurgie. 69. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Mexikanischen und Kolumbianischen Gesellschaft für Neurochirurgie. Münster, 03.-06.06.2018. Düsseldorf: German Medical Science GMS Publishing House; 2018. DocP058

doi: 10.3205/18dgnc399, urn:nbn:de:0183-18dgnc3997

Published: June 18, 2018

© 2018 Köber et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. See license information at http://creativecommons.org/licenses/by/4.0/.

Outline

Text

Objective: Carmustine wafers are approved for the treatment of primary and recurrent HGG. Here, we analysed the impact of carmustine implantation in recurrent glioblastoma patients.

Methods: Inclusion criteria for this monocentric, retrospective data analysis were: patients with (1) primary glioblastoma, (2) STUPP therapy, (3) with (Group A) and without (Group B) carmustine implantation in 1 recurrence operation.

Results: Between 2010 and 2017 214 patients received intraoperative carmustine implantation. 92 patients with carmustine implantation complied the inclusion criteria (group A), 38 without carmustine (group B).

There was no significant difference in PFS after 1 recurrence between both groups (A: median 4.7 m, B: median 4.0 m (p=0.52)), as well as in OS (A: median 17.0 m, B: median 18.0m, (p= 0.997)). The median OS after first recurrence was decreased in patients with carmustine implantation (group A: 7.5 m (CI 5.9-9.2) compared to group B (9.4 m (CI 7.4-11.3)), p=0.193 and also lower than in recent published data (10.3 m CI (9.0-11.33)). Regarding side effects, we observed 8 postoperative infections (8.3%) in group A, in group B 4 infections (10.4%).

Conclusion: There was no significant difference after carmustine implantation regarding PFS, OS or postoperative complications after first recurrence. Limitation of this analysis: (1) no adjustment for bias, (2) regarding the relative low OS the exclusion of pseudoprogression must be taken to account.